Literature DB >> 15383753

Molecular findings in Barrett's epithelium.

Andrea Tannapfel1.   

Abstract

Barrett's metaplasia is a premalignant condition and remains the number one risk factor for developing adenocarcinoma. The histologic changes leading to adenocarcinoma are accompanied by genetic disturbances of the epithelial cells itself as well as the surrounding stroma. Genetic and epigenetic events affect the cell cycle, leading to growth self-sufficiency and ignoration of antigrowth signals. The balance of cell turnover is instable by avoidance of apoptosis and a general limitless of the replicative potential of the (mutated) stem cells. Sustained angiogenesis, not only a consequence of chronic inflammation, may precede invasion of genetically instable (aneuploid) cells. The principal genetic changes in Barrett's carcinogenesis are comparable to those known from other epithelial malignancies. Loss of p16 gene expression (by deletion or hypermethylation), the loss of p53 expression (by mutation and deletion), the increase in cyclin expression, and the losses of Rb, APC as well as various chromosomal loci have been reported. Since these genetic or epigenetic alterations are neither tumor nor stage specific, they could not gain diagnostic significance as biomarkers until now. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15383753     DOI: 10.1159/000080311

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  7 in total

1.  Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.

Authors:  Doerthe Kuester; Altaf A Dar; Christopher C Moskaluk; Sabine Krueger; Frank Meyer; Roland Hartig; Manfred Stolte; Peter Malfertheiner; Hans Lippert; Albert Roessner; Wael El-Rifai; Regine Schneider-Stock
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

2.  Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.

Authors:  I Tischoff; U R Hengge; M Vieth; C Ell; M Stolte; A Weber; W E Schmidt; A Tannapfel
Journal:  Gut       Date:  2007-03-21       Impact factor: 23.059

3.  Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Authors:  Doerthe Kuester; Wa'el El-Rifai; DunFa Peng; Petra Ruemmele; Ivonne Kroeckel; Brigitte Peters; Christopher A Moskaluk; Manfred Stolte; Klaus Mönkemüller; Frank Meyer; Hans-Ulrich Schulz; Arndt Hartmann; Albert Roessner; Regine Schneider-Stock
Journal:  Cancer Lett       Date:  2008-11-21       Impact factor: 8.679

4.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

5.  Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Eric Smith; Neville J De Young; Sandra J Pavey; Nicholas K Hayward; Derek J Nancarrow; David C Whiteman; B Mark Smithers; Andrew R Ruszkiewicz; Andrew D Clouston; David C Gotley; Peter G Devitt; Glyn G Jamieson; Paul A Drew
Journal:  Mol Cancer       Date:  2008-10-02       Impact factor: 27.401

6.  Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.

Authors:  Fumiaki Sato; Zhe Jin; Karsten Schulmann; Jean Wang; Bruce D Greenwald; Tetsuo Ito; Takatsugu Kan; James P Hamilton; Jian Yang; Bogdan Paun; Stefan David; Alexandru Olaru; Yulan Cheng; Yuriko Mori; John M Abraham; Harris G Yfantis; Tsung-Teh Wu; Mary B Fredericksen; Kenneth K Wang; Marcia Canto; Yvonne Romero; Ziding Feng; Stephen J Meltzer
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

7.  Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.

Authors:  Zhe Jin; Liang Wang; Ziyi Cao; Yulan Cheng; Yan Gao; Xianling Feng; Si Chen; Huimin Yu; Wenjing Wu; Zhenfu Zhao; Ming Dong; Xiaojing Zhang; Jie Liu; Xinmin Fan; Yuriko Mori; Stephen J Meltzer
Journal:  BMC Cancer       Date:  2014-05-20       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.